Eradication of Helicobacter pylori infection as a strategy for the prevention of stomach cancer: statements of MaastrichT-V consensus (2015)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review article reflects the main statements of Maastricht-V Consensus (2015) concerning the role of Helicobacter pylori infection in the development of stomach cancer, as well as the significance of eradication therapy as the main strategy for canceroprevention. Eradication of H. pylori infection significantly reduces the risk of stomach cancer, leads to the resolution of inflammatory changes in the mucous membrane of the stomach, and prevents the development of precancerous lesions. In the absence of intestinal metaplasia, eradication therapy leads to regression of atrophy of the gastric mucosa, and thus prevents the progression of precancerous lesions to neoplastic processes. Eradication of H. pylori is economically feasible as a part of the prevention of stomach cancer in a population at high risk of developing this disease.

Full Text

Restricted Access

About the authors

I. V Mayev

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

D. N Andreev

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

Email: dna-mit8@mail.ru
PhD, Teaching Assistant at the Department of Propedeutics of Internal Diseases and Gastroenterology

A. A Samsonov

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

D. T Dicheva

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

A. V Zaborovsky

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

E. V Partsvania-Vinogradova

FSBEI HE “MoscowState Medical Stomatological University n.a. A.I. Evdokimov" of RMH

References

  1. Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М., 2016, 256 с.
  2. Morgan D.R., Crowe S.E. Helicobacter pylori infection. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by M. Feldman, L.S. Friedman, L.J. Brandt. 10th ed. 2015.
  3. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевтический архив. 2014;3:94-9.
  4. Маев И.В., Андреев Д.Н., Самсонов А.А., Дичева Д.Т., Парцваниа-Виноградова Е.В. Эволюция представлений о дефиниции, классификации, диагностике и лечении гастрита, ассоциированного с инфекцией Helicobacter pylori (по материалам киотского консенсуса, 2015). Фарматека. 2016;6:24-33.
  5. Abrams J.A., Quante M. Adenocarcinoma of the Stomach and Other. In.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by M. Feldman, L.S. Friedman, L.J. Brandt. 10th ed. 2015.
  6. Маев И.В., Андреев Д.Н. Рак желудка: факторы риска и возможности канцеропревенции. Consilium Medicum. 2014;16(12):45-50.
  7. Чиссов В.И., Старинский В.В., Петрова Г.В. (ред.) Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М., 2013.
  8. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 1994;61:1-241.
  9. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol. Biomarkers Prev. 1996;5:477-81.
  10. Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. Management of Helicobacter pylori infection the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30.
  11. Barreto-Zuniga R., Maruyama M., Kato Y., Aizu K., Ohta H., Takekoshi T., Bernal S.F Significance of Helicobacter pylori infection as a risk factor in gastric cancer: serological and histological studies. J. Gastroenterol. 1997;32:289-94.
  12. Miehlke S., Hackelsberger A., Meining A., von Arnim U., Muller P., Ochsenkuhn T., Lehn N., Malfertheiner P., Stolte M., Bayerdorffer E. Histological diagnosis of Helicobacter pylori gastritis is predictive of a high risk of gastric carcinoma. Int. J. Cancer. 1997;73:837-39.
  13. Nomura A.M., Stemmermann G.N., Chyou P.H. Gastric cancer among the Japanese in Hawaii. Jpn. J. Cancer Res. 1995;86:916-23.
  14. Forman D., Newell D.G., Fullerton F., Yarnell J.W., Stacey A.R., Wald N., Sitas F. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302-305.
  15. Kamangar F., Qiao Y.L., Blaser M.J., Sun X.D., Katki H., Fan J.H., Perez-Perez G.I., Abnet C.C., Zhao P., Mark S.D., Taylor P.R., Dawsey S.M. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br. J. Cancer. 2007;96:172-76.
  16. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001;345:784-89.
  17. Matos J.I., de Sousa H.A., Marcos-Pinto R., Dinis-Ribeiro M. Helicobacter pylori CagA and VacA genotypes and gastric phenotype: a meta-analysis. Eur. J. Gastroenterol. Hepatol. 2013;25(12):1431-41.
  18. Wroblewski L.E., Peek R.M. Jr. Helicobacter pylori in gastric carcinogenesis mechanisms. Gastroenterol. Clin. N. Am. 2013;42:285-98.
  19. Hansson L.E., Engstrand L., Nyrén O., Evans D.J. Jr, Lindgren A., Bergström R., Andersson B., Athlin L., Bendtsen O., Tracz P. Helicobacter pylori infection: independent risk indicator of gastric adenocarcinoma. Gastroenterology. 1993;105:1098-103.
  20. Hansson L.R., Engstrand L., Nyrén O., Lindgren A. Prevalence of Helicobacter pylori infection in subtypes of gastric cancer. Gastroenterology. 1995;109:885-88.
  21. BornscheinJ.,Selgrad M., Warnecke M., Kuester D., Wex T., Malfertheiner P. H. pylori infection is a key risk factor for proximal gastric cancer. Dig. Dis. Sci. 2010;55:3124-31.
  22. Abrams J.A., Gonsalves L., Neugut A.I. Diverging trends in the incidence of reflux-related and Helicobacter pylori-related gastric cardia cancer. J. Clin. Gastroenterol. 2013;47:322-27.
  23. Kamada T., Kurose H., Yamanaka Y., Manabe N., Kusunoki H., Shiotani A., Inoue K., Hata J., Matsumoto H., Akiyama T., Hirai T., Sadahira Y., Haruma K. Relationship between gastroesophageal junction adenocarcinoma and Helicobacter pylori infection in Japan. Digestion. 2012;85:256-60.
  24. Fuccio L., Zagari R.M., Eusebi L.H., Laterza L., Cennamo V., Ceroni L., Grilli D., Bazzoli F. Metaanalysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 2009;151(2):121-28.
  25. Chen H.N., Wang Z., Li X., Zhou Z.G. Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a metaanalysis. Gastric Cancer. 2016;19(1):166-75.
  26. lee Y.C., Chiang T.H., Chou C.K., Tu Y.K., Liao W.C., Wu M.S., Graham D.Y. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150(5):1113-24.
  27. González C.A., Megraud F., Buissonniere A., Lujan Barroso L., Agudo A., Duell E.J., et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann. Oncol. 2012;23:1320-24.
  28. Ramon J.M., Serra L., Cerdo C., Oromi J. Dietary factors and gastric cancer risk. A case-control study in Spain. Cancer. 1993;71:1731-35.
  29. Nazario C.M., Szklo M., Diamond E., Román-Franco A., Climent C., Suarez E., Conde J.G. Salt and gastric cancer: A case-control study in Puerto Rico. Int. J. Epidemiol. 1993;22:790-97.
  30. Loh J.T., Torres V.J., Cover T.L. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res. 2007;67:4709-15.
  31. Gamboa-Dominguez A, Ubbelohde T., Saqui-Salces M., Romano-Mazzoti L., Cervantes M., Domlnguez-Fonseca C., de la Luz Estreber M., Rufz-Palacios G.M. Salt and stress synergize H. pylori-induced gastric lesions, cell proliferation, and p21 expression in Mongolian gerbils. Dig. Dis. Sci. 2007;52:1517-26.
  32. Zhou L., Sung J.J., Lin S., Jin Z., Ding S., Huang X., Xia Z., Guo H., Liu J., Chao W. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin. Med. J. 2003;116:11-4.
  33. Gatta L., Di Mario F., Vaira D., Rugge M., Franzè A., Plebani M., Cavestro G.M., Lucarini P., Lera M., Scarpignato C. Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori. Clin. Gastroenterol. Hepatol. 2011;9:440-42.
  34. Leja M., Lapina S., Polaka I., Rudzite D., Vilkoite I., Daugule I., Belkovets A., Pimanov S., Makarenko J., Tolmanis I., Lejnieks A., Boka V., Rumba-Rozenfelde I., Vikmanis U. Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy. Medicina (Kaunas). 2014;50:8-13.
  35. Okubo M., Tahara T., Shibata T., Nakamura M., Yoshioka D., Maeda Y., Yonemura J., Ishizuka T., Arisawa T., Hirata I. Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication. J. Gastroenterol. 2011;46:175-82.
  36. Lee Y.C., Chen T.H., Chiu H.M., Shun C.T., Chiang H., Liu T.Y., Wu M.S., Lin J.T. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676-82.
  37. Jung D.H., Kim J.H., Chung H.S., Park J.C., Shin S.K., Lee S.K., Lee Y.C. Helicobacter pylori eradication on the prevention of metachronous lesions after endoscopic resection of gastric neoplasm: a meta-analysis. PLoS One. 2015;10:e0124725.
  38. Arkkila P.E., Seppälä K., Färkkilä M.A., Veijola L., Sipponen P. Helicobacter pylori eradication in the healing of atrophic gastritis: a one-year prospective study. Scand. J. Gastroenterol. 2006;41:782-90.
  39. Mera R., Fontham E.T., Bravo L.E., Bravo J.C., Piazuelo M.B., Camargo M.C., Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536-40.
  40. Rokkas T., Pistolias D., Sechopoulos P, Robotis I., Margantinis G. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12(suppl 2):32-8.
  41. Kong Y.J., Yi H.G., Dai J.C., Wei M.X. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J. Gastroenterol. 2014;20:5903-11.
  42. Ma J.L., Zhang L., Brown L.M., Li J.Y., Shen L., Pan K.F., Liu W.D., Hu Y., Han Z.X., Crystal-Mansour S., Pee D., Blot W.J., Fraumeni J.F. Jr, You W.C., Gail M.H. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J. Natl. Cancer Inst. 2012;104:488-92.
  43. Wong B.C., Lam S.K., Wong W.M., Chen J.S., Zheng T.T., Feng R.E., Lai K.C., Hu W.H., Yuen S.T., Leung S.Y., Fong D.Y., Ho J., Ching C.K., Chen J.S.; China Gastric CancerStudy Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-94.
  44. Areia M., Carvalho R., Cadime A.T., Rocha Gonçalves F., Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter. 2013;18(5):325-37.
  45. Roderick P., Davies R., Raftery J., Crabbe D., Pearce R., Patel P., Bhandari P. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J. Med. Screen. 2003;10:148-56.
  46. Vergara M., Catalán M., Gisbert J.P., Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 2005;21:1411-18.
  47. Маев И.В., Андреев Д.Н., Дичева Д.Т. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016;2:49-54.
  48. Fock K.M., Katelaris P., Sugano K., Ang T.L., Hunt R., Talley N.J., Lam S.K., Xiao S.D., Tan H.J., Wu C.Y., Jung H.C., Hoang B.H., Kachintorn U., Goh K.L., Chiba T., Rani A.A.; Second Asia-Pacific Conference. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J. Gastroenterol. Hepatol. 2009;24:1587-600.
  49. Pan K.F., Zhang L., Gerhard M., Ma J.L., Liu W.D., Ulm K., Wang J.X., Zhang L., Zhang Y., Bajbouj M., Zhang L.F., Li M., Vieth M., Liu R.Y., Quante M., Wang L.H., Suchanek S., Zhou T., Guan W.X., Schmid R., Classen M., You W.C. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut. 2016;65:9-18.
  50. Herrero R., Parsonnet J., Greenberg E.R. Prevention of gastric cancer. JAMA. 2014;312:1197-98.
  51. Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - «ABC method». Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci. 2011;87(7):405-4.
  52. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer. 2006;9:245-53.
  53. Watabe H., Mitsushima T., Yamaji Y., Okamoto M., Wada R., Kokubo T., Doi H., Yoshida H., Kawabe T., Omata M. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut. 2005;54:764-68.
  54. Tanaka M., Ono H., Hasuike N., Takizawa K. Endoscopic submucosal dissection of early gastric cancer. Digestion. 2008;77(Suppl. 1): 23-8.
  55. Isajevs S., Liepniece-Karele I., Janciauskas D., Moisejevs G., Putnins V., Funka K., Kikuste I., Vanags A., Tolmanis I., Leja M. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch. 2014;464:403-7.
  56. Capelle L.G., de Vries A.C., Haringsma J., Ter Borg F., de Vries R.A., Bruno M.J., van Dekken H., Meijer J., van Grieken N.C., Kuipers E.J. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest. Endosc. 2010;71:1150-58.
  57. Bergman M., Huikko S., Huovinen P., Paakkari P., Seppälä H; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2006;50:3646-50.
  58. Megraud F. Potential impact of bacterial resistance after population-based Helicobacter pylori treatment. In: Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon: IARC, 2014:80-7.
  59. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Медицинский совет. 2013;10:11-5.
  60. Maev I., Andreev D., Kucheryavyi Yu., Dicheva D. Molecular mechanisms of Helicobacter pylori antibiotic resistance. Archiv EuroMedica. 2013;3(2):27-9.
  61. Gisbert J.P., Marla Pajares J. Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review. Med. Clin. 2001;116:111-16.
  62. Zeng M., Mao X.H., Li J.X., Tong W.D., Wang B., Zhang Y.J., Guo G., Zhao Z.J., Li L., Wu D.L., Lu D.S., Tan Z.M., Liang H.Y., Wu C., Li D.H., Luo P., Zeng H., Zhang W.J., Zhang J.Y., Guo B.T., Zhu F.C., Zou Q.M. Efficacy, safety, and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1457-64.
  63. Maev I.V., Andreev D.N., Kucheryavyi Yu.A., Dicheva D.T. Host factors influencing the eradication rate of Helicobacter pylori. World Appl. Sci. J. 2014;30:134-40.
  64. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Актуальные возможности оптимизации антихеликобактерной терапии. Лечащий врач. 2014;4:73-9.
  65. Ивашкин В.Т., Шептулин А.А., Маев И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению язвенной болезни. Рос. журн. гастроэнтерол. гепатол. колопроктол. 2016;26(6):40-54.
  66. Serrano D., et al. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/ pharmacodynamics of proton pump inhibitor-containing Helicobacter pylori treatment. Curr. Drug Metab. 2012;13: 1303-12.
  67. Padol S., Yuan Y., Thabane M., et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol. 2006;101(7):1467-75.
  68. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gisbert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol. Ther. 2012; 36(5):414-25.
  69. Kuo C.H., Wang S.S., Hsu W.H., et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265-72.
  70. Kuo C.H., Lu C.Y., Shih H.Y., Liu C.J., Wu M.C., Hu H.M., Hsu W.H., Yu F.J., Wu D.C., Kuo F.C. CYP2C19 polymorphism influences Helicobacter pylori eradication. World J. Gastroenterol. 2014;20(43):16029-36.
  71. Ohara T., Goshi S., Taneike I., Tamura Y., Zhang H.M., Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2): 125-29.
  72. Zhang Z., Liu Z.Q., Zheng P.Y., Tang F.A., Yang P.C. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J. Gastroenterol. 2010;16(10):1279-84.
  73. Niv Y. Helicobacter pylori and gastric mucin expression: A systematic review and metaanalysis. World J. Gastroenterol. 2015; 21(31):9430-36.
  74. Skoczylas T., Sarosiek I., Sostarich S., et al. Signicant enhancement of gastric mucin content after rabeprazole administration: its potential clinical signicance in acid-related disorders. Dig. Dis. Sci. 2003;48: 322-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies